New developments in Toll-like receptor targeted therapeutics

Current Opinion in Pharmacology

Volumn 12, Issue 4, 2012, Pages 510-518

  Connolly, Dympna J ^a   O'Neill, Luke Aj ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

852A; ANA 773; AVE 0675; AZD 1419; AZD 8848; BEVACIZUMAB; CBLB 502; CETUXIMAB; CHEMICAL COMPOUND; CPG 52364; DIMS 1050; DV 1179; ERITORAN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GLUCOCORTICOID; HEPATITIS B VACCINE; IBUDILAST; IMIQUIMOD; IMO 2055; IMO 2125; IMO 3100; IMO 8400; IRINOTECAN; KAPPAPROCT; NI 0101; OPN 305; PLANT EXTRACT; POLLINEX QUATTRO; QAX 935; RAGWEED POLLEN EXTRACT; RESIQUIMOD; RINTATOLIMOD; SAR 21609; SD 101; SMP 105; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAX 102; VAX 125; VTX 1463;

ACTINIC KERATOSIS; ACUTE ISCHEMIC RENAL FAILURE; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ASTHMA; BASAL CELL CARCINOMA; CHRONIC FATIGUE SYNDROME; CHRONIC INFLAMMATION; CHRONIC PAIN; COLORECTAL CANCER; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG POTENCY; GENITAL HERPES; HAY FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART MUSCLE ISCHEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOREGULATION; INFECTION; INFLAMMATION; INFLUENZA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTATIC MELANOMA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; STROKE; SUPERFICIAL BASAL CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; WITHDRAWAL SYNDROME;

ANIMALS; HUMANS; IMMUNE SYSTEM DISEASES; NEOPLASMS; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 84865032889     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.06.002     Document Type: Review

References (68)

1. A. Poltorak, X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, and C. Galanos Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene Science 282 1998 2085 2088
2. T. Kawai, and S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 2010 373 384
3. S. Knapp, S. Muller, G. Digilio, T. Bonaldi, M.E. Bianchi, and G. Musco The long acidic tail of high mobility group box 1 (HMGB1) protein forms an extended and flexible structure that interacts with specific residues within and between the HMG boxes Biochemistry 43 2004 11992 11997
4. A. Biragyn, P.A. Ruffini, C.A. Leifer, E. Klyushnenkova, A. Shakhov, O. Chertov, A.K. Shirakawa, J.M. Farber, D.M. Segal, and J.J. Oppenheim Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2 Science 298 2002 1025 1029
5. L.A. O'Neill, and A.G. Bowie The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling Nat Rev Immunol 7 2007 353 364
6. D.N. Cook, D.S. Pisetsky, and D.A. Schwartz Toll-like receptors in the pathogenesis of human disease Nat Immunol 5 2004 975 979
7. E.J. Hennessy, A.E. Parker, and L.A. O'Neill Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9 2010 293 307
8. E.A. Misch, and T.R. Hawn Toll-like receptor polymorphisms and susceptibility to human disease Clin Sci (Lond) 114 2008 347 360
9. R. Woodrick, and E.M. Ruderman Anti-interleukin-6 therapy in rheumatoid arthritis Bull NYU Hosp Jt Dis 68 2010 211 217
10. N. Thalayasingam, and J.D. Isaacs Anti-TNF therapy Best Pract Res Clin Rheumatol 25 2011 549 567
11. H. Hemmi, T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat Immunol 3 2002 196 200
12. R. Brunner, E. Jensen-Jarolim, and I. Pali-Scholl The ABC of clinical and experimental adjuvants - a brief overview Immunol Lett 128 2010 29 35
13. T. Kawai, and S. Akira Innate immune recognition of viral infection Nat Immunol 7 2006 131 137
14. A. AG, S.K. Tyring, and T. Rosen Beyond a decade of 5% imiquimod topical therapy J Drugs Dermatol 8 2009 467 474
15. N. Somani, and J.K. Rivers Imiquimod 5% cream for the treatment of actinic keratoses Skin Therapy Lett 10 2005 1 6
16. J.K. Geisse, P. Rich, A. Pandya, K. Gross, K. Andres, A. Ginkel, and M. Owens Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study J Am Acad Dermatol 47 2002 390 398
17. C. Schiessl, C. Wolber, M. Tauber, F. Offner, and R. Strohal Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up J Drugs Dermatol 6 2007 507 513
18. K.E. Mark, L. Corey, T.C. Meng, A.S. Magaret, M.L. Huang, S. Selke, H.B. Slade, S.K. Tyring, T. Warren, and S.L. Sacks Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial J Infect Dis 195 2007 1324 1331
19. A.Z. Dudek, C. Yunis, L.I. Harrison, S. Kumar, R. Hawkinson, S. Cooley, J.P. Vasilakos, K.S. Gorski, and J.S. Miller First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer Clin Cancer Res 13 2007 7119 7125
20. L.I. Harrison, C. Astry, S. Kumar, and C. Yunis Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans J Clin Pharmacol 47 2007 962 969
21. R. Dummer, A. Hauschild, J.C. Becker, J.J. Grob, D. Schadendorf, V. Tebbs, J. Skalsky, K.C. Kaehler, S. Moosbauer, and R. Clark An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma Clin Cancer Res 14 2008 856 864
22. J.F. Bergmann, J. de Bruijne, D.M. Hotho, R.J. de Knegt, A. Boonstra, C.J. Weegink, A.A. van Vliet, J. van de Wetering, S.P. Fletcher, and L.A. Bauman Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV Aliment Pharmacol Ther 34 2011 443 453
23. A. Boonstra, B.S. Liu, Z.M. Groothuismink, J.F. Bergmann, J. de Bruijne, D.M. Hotho, B.E. Hansen, A.A. van Vliet, J. van de Wetering de Rooij, and S.P. Fletcher Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7 Antivir Ther 17 2011 657 667
24. K.B. Gorden, K.S. Gorski, S.J. Gibson, R.M. Kedl, W.C. Kieper, X. Qiu, M.A. Tomai, S.S. Alkan, and J.P. Vasilakos Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 J Immunol 174 2005 1259 1268
25. F. Horak VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis Expert Opin Investig Drugs 20 2011 981 986
26. H. Kanzler, F.J. Barrat, E.M. Hessel, and R.L. Coffman Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists Nat Med 13 2007 552 559
27. S. Agrawal, and E.R. Kandimalla Synthetic agonists of Toll-like receptors 7, 8 and 9 Biochem Soc Trans 35 2007 1461 1467
28. B.P. Sablan, D.J. Kim, N.G. Barzaga, W.C. Chow, M. Cho, S.H. Ahn, S.G. Hwang, J.H. Lee, H. Namini, and W.L. Heyward Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine Vaccine 30 2012 2689 2696
29. S.A. Halperin, B. Ward, C. Cooper, G. Predy, F. Diaz-Mitoma, M. Dionne, J. Embree, A. McGeer, P. Zickler, and K.H. Moltz Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age Vaccine 30 2012 2556 2563
30. W.U. Kim, A. Sreih, and R. Bucala Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention Autoimmun Rev 8 2009 204 208
31. C. Guiducci, M. Gong, Z. Xu, M. Gill, D. Chaussabel, T. Meeker, J.H. Chan, T. Wright, M. Punaro, and S. Bolland TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus Nature 465 2010 937 941
32. F.J. Barrat, T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms Eur J Immunol 37 2007 3582 3586
33. M.S. Jin, S.E. Kim, J.Y. Heo, M.E. Lee, H.M. Kim, S.G. Paik, H. Lee, and J.O. Lee Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide Cell 130 2007 1071 1082
34. J.Y. Kang, X. Nan, M.S. Jin, S.J. Youn, Y.H. Ryu, S. Mah, S.H. Han, H. Lee, S.G. Paik, and J.O. Lee Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer Immunity 31 2009 873 884
35. J. Favre, P. Musette, V. Douin-Echinard, K. Laude, J.P. Henry, J.F. Arnal, C. Thuillez, and V. Richard Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction Arterioscler Thromb Vasc Biol 27 2007 1064 1071
36. J.C. Leemans, G. Stokman, N. Claessen, K.M. Rouschop, G.J. Teske, C.J. Kirschning, S. Akira, T. van der Poll, J.J. Weening, and S. Florquin Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney J Clin Invest 115 2005 2894 2903
37. F. Arslan, M.B. Smeets, L.A. O'Neill, B. Keogh, P. McGuirk, L. Timmers, C. Tersteeg, I.E. Hoefer, P.A. Doevendans, and G. Pasterkamp Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody Circulation 121 2010 80 90
38. S. Selejan, J. Poss, F. Walter, M. Hohl, R. Kaiser, A. Kazakov, M. Bohm, and A. Link Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shock Eur Heart J 33 2011 1085 1094
39. F. Arslan, J.H. Houtgraaf, B. Keogh, K. Kazemi, R. de Jong, W.J. McCormack, L.A. O'Neill, P. McGuirk, L. Timmers, and M.B. Smeets Treatment with OPN-305, a humanized anti-Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs Circ Cardiovasc Interv 5 2012 279 287
40. C.A. Farrar, B. Keogh, W. McCormack, A. O'Shaughnessy, A. Parker, M. Reilly, and S.H. Sacks Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury FASEB J 26 2012 799 807
41. S.N. Ultaigh, T.P. Saber, J. McCormick, M. Connolly, J. Dellacasagrande, B. Keogh, W. McCormack, M. Reilly, L.A. O'Neill, and P. McGuirk Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures Arthritis Res Ther 13 2011 R33
42. M. Murata Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors Cancer Sci 99 2008 1435 1440
43. M. Miyauchi, M. Murata, K. Shibuya, E. Koga-Yamakawa, Y. Uenishi, N. Kusunose, M. Sunagawa, I. Yano, and Y. Kashiwazaki Arabino-mycolates derived from cell-wall skeleton of Mycobacterium bovis BCG as a prominent structure for recognition by host immunity Drug Discov Ther 5 2011 130 135
44. R. Shimazu, S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4 J Exp Med 189 1999 1777 1782
45. S.D. Wright, R.A. Ramos, P.S. Tobias, R.J. Ulevitch, and J.C. Mathison CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein Science 249 1990 1431 1433
46. T. Mizuno, T. Kurotani, Y. Komatsu, J. Kawanokuchi, H. Kato, N. Mitsuma, and A. Suzumura Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia Neuropharmacology 46 2004 404 411
47. P. Rolan, J.A. Gibbons, L. He, E. Chang, D. Jones, M.I. Gross, J.B. Davidson, L.M. Sanftner, and K.W. Johnson Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses Br J Clin Pharmacol 66 2008 792 801
48. M.R. Hutchinson, Y. Zhang, M. Shridhar, J.H. Evans, M.M. Buchanan, T.X. Zhao, P.F. Slivka, B.D. Coats, N. Rezvani, and J. Wieseler Evidence that opioids may have toll-like receptor 4 and MD-2 effects Brain Behav Immun 24 2010 83 95
49. F.Y. Tanga, N. Nutile-McMenemy, and J.A. DeLeo The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy Proc Natl Acad Sci USA 102 2005 5856 5861
50. A. Ledeboer, T. Liu, J.A. Shumilla, J.H. Mahoney, S. Vijay, M.I. Gross, J.A. Vargas, L. Sultzbaugh, M.D. Claypool, and L.M. Sanftner The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain Neuron Glia Biol 2 2006 279 291
51. H.M. Kim, B.S. Park, J.I. Kim, S.E. Kim, J. Lee, S.C. Oh, P. Enkhbayar, N. Matsushima, H. Lee, and O.J. Yoo Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran Cell 130 2007 906 917
52. E. Czeslick, A. Struppert, A. Simm, and A. Sablotzki E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes Inflamm Res 55 2006 511 515
53. Y.N. Wong, D. Rossignol, J.R. Rose, R. Kao, A. Carter, and M. Lynn Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study J Clin Pharmacol 43 2003 735 742
54. M. Lynn, D.P. Rossignol, J.L. Wheeler, R.J. Kao, C.A. Perdomo, R. Noveck, R. Vargas, T. D'Angelo, S. Gotzkowsky, and F.G. McMahon Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia J Infect Dis 187 2003 631 639
55. E. Bennett-Guerrero, H.P. Grocott, J.H. Levy, K.A. Stierer, C.W. Hogue, A.T. Cheung, M.F. Newman, A.A. Carter, D.P. Rossignol, and C.D. Collard A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass Anesth Analg 104 2007 378 383
56. M. Tidswell, W. Tillis, S.P. Larosa, M. Lynn, A.E. Wittek, R. Kao, J. Wheeler, J. Gogate, and S.M. Opal Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis Crit Care Med 38 2010 72 83
57. A. Barochia, S. Solomon, X. Cui, C. Natanson, and P.Q. Eichacker Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies Expert Opin Drug Metab Toxicol 7 2011 479 494
58. D.C. Angus The search for effective therapy for sepsis: back to the drawing board? JAMA 306 2011 2614 2615
59. K.J. Drachenberg, A.W. Wheeler, P. Stuebner, and F. Horak A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections Allergy 56 2001 498 505
60. D.R. Strayer, W.A. Carter, B.C. Stouch, S.R. Stevens, L. Bateman, P.J. Cimoch, C.W. Lapp, D.L. Peterson, and W.M. Mitchell A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome PLoS ONE 7 2012 e31334
61. R.J. Suhadolnik, N.L. Reichenbach, P. Hitzges, M.E. Adelson, D.L. Peterson, P. Cheney, P. Salvato, C. Thompson, M. Loveless, and W.E. Muller Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome In Vivo 8 1994 599 604
62. C.F. Nicodemus, L. Wang, J. Lucas, B. Varghese, and J.S. Berek Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy Am J Obstet Gynecol 202 2010 608 e601-608
63. N. Fukuzawa, M. Petro, W.M. Baldwin 3rd, A.V. Gudkov, and R.L. Fairchild A TLR5 agonist inhibits acute renal ischemic failure J Immunol 187 2011 3831 3839
64. C.B. Turley, R.E. Rupp, C. Johnson, D.N. Taylor, J. Wolfson, L. Tussey, U. Kavita, L. Stanberry, and A. Shaw Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults Vaccine 29 2011 5145 5152
65. D.N. Taylor, J.J. Treanor, C. Strout, C. Johnson, T. Fitzgerald, U. Kavita, K. Ozer, L. Tussey, and A. Shaw Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI) Vaccine 29 2011 4897 4902
66. S.I. Yoon, O. Kurnasov, V. Natarajan, M. Hong, A.V. Gudkov, A.L. Osterman, and I.A. Wilson Structural basis of TLR5-flagellin recognition and signaling Science 335 2012 859 864
67. J. Garaude, A. Kent, N. van Rooijen, and J.M. Blander Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses Sci Transl Med 4 2012 120ra116
68. N.A. Marshall, K.C. Galvin, A.M. Corcoran, L. Boon, R. Higgs, and K.H. Mills Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+IL-17+ polyfunctional T cells that mediate rejection of murine tumors Cancer Res 72 2012 581 591